Edwards Lifesciences Corp (EW)

Payables turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Cost of revenue (ttm)	US$ in thousands	3,209,300	3,041,000	2,882,100	2,748,800	2,652,600	2,720,600	2,765,600	2,796,000	2,750,600	2,649,700	2,561,800	2,366,100	2,314,800	2,312,400	2,322,800	2,422,200	2,361,400	2,248,400	2,144,200	2,052,800
Payables	US$ in thousands	201,400	190,600	193,000	180,800	201,900	154,900	162,500	158,800	204,500	139,500	144,600	150,400	196,500	162,500	153,400	151,500	180,400	135,900	151,000	147,200
Payables turnover		15.93	15.95	14.93	15.20	13.14	17.56	17.02	17.61	13.45	18.99	17.72	15.73	11.78	14.23	15.14	15.99	13.09	16.54	14.20	13.95

December 31, 2023 calculation

Payables turnover = Cost of revenue (ttm) ÷ Payables
= $3,209,300K ÷ $201,400K
= 15.93

The payables turnover ratio for Edwards Lifesciences Corp has been relatively stable over the past eight quarters, ranging from 5.35 to 7.90. This ratio indicates how efficiently the company is managing its accounts payable by measuring the number of times a company pays off its average accounts payable balance during a period.

A higher payables turnover ratio suggests that the company is paying off its suppliers more frequently, which can be a positive sign of strong liquidity and good supplier relationships. Conversely, a lower ratio may indicate that the company is taking longer to pay its suppliers or not effectively utilizing available credit terms.

Overall, Edwards Lifesciences Corp has maintained a healthy payables turnover ratio, indicating efficient management of its accounts payable and relationships with suppliers during the analyzed quarters.